+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

High occurrence of blaCMY-1 AmpC lactamase producing Escherichia coli in cases of complicated urinary tract infection (UTI) from a tertiary health care centre in north India



High occurrence of blaCMY-1 AmpC lactamase producing Escherichia coli in cases of complicated urinary tract infection (UTI) from a tertiary health care centre in north India



Indian Journal of Medical Research 136(2): 289-291



AmpC beta lactamase producing Gram-negative bacteria have emerged worldwide. It is important to distinguish plasmid mediated AmpC β lactamases from chromosomally mediated enzymes for surveillance, epidemiology and hospital infection control as plasmid mediated genes can spread to other organisms. Occurrence of blaCMY-1 AmpC β-lactamase, a plasmid mediated cephamycinase was studied in 100 consecutive isolates of Escherichia coli from cases of complicated urinary tract infection (UTI). Screening for AmpC production was done by modified Hodge test, three dimensional test and AmpC disk test. All isolates showing a positive result by 2 out of 3 tests were then tested for blaCMY-1 gene by PCR. Fifty nine isolates were positive for AmpC β lactamase production, 56.6 per cent were positive by PCR. Eight out of 13 isolates which were negative by EDTA disk method were positive by PCR, whereas none of the isolates negative by 3D and modified Hodge test was positive by PCR. Among admitted patients urinary catheterisation was the major risk factor followed by obstructive uropathy, three patients developed urosepsis. High occurrence of blaCMY-1 AmpC β-lactamase warrants health care workers to endorse good hospital practices.

(PDF emailed within 1 workday: $29.90)

Accession: 053537306

Download citation: RISBibTeXText

PMID: 22960897


Related references

In vitro Resistance of extended-spectrum (ESBL) versus AmpC-phenotype (AmpC) beta-lactamase-producing Escherichia coli urinary isolates against six first-line oral antibiotics commonly used for community-acquired urinary-tract infections. 2005

Complicated urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli. Urology Annals 6(2): 112-113, 2014

Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials. New Zealand Medical Journal 128(1410): 50-59, 2015

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model. Antimicrobial Agents and ChemoTherapy 62(6), 2018

Malakoplakia in a patient with complicated urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli. Journal of Microbiology, Immunology, and Infection 48(3): 345-346, 2016

Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. International Urology and Nephrology 47(7): 1059-1066, 2016

Detection and epidemiology of plasmid-mediated AmpC β-lactamase producing Escherichia coli in two Irish tertiary care hospitals. Journal of Global Antimicrobial Resistance 3(4): 242-246, 2016

Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. Journal of ChemoTherapy 22(5): 355-357, 2011

Nosocomial urinary tract infection due to Leuconostoc mesenteroides at a tertiary care centre in north India. Indian Journal of Medical Research 122(2): 178-179, 2005

Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection. Antimicrobial Agents and ChemoTherapy 61(11), 2017

Dissemination and characterization of extended spectrum β-lactamase, AmpC β-lactamase and metallo β-lactamase producing Escherichia coli from livestock and poultry in Northeastern India: A molecular surveillance approach. Journal of Global Antimicrobial Resistance 2019, 2019

Two cases of human urinary tract infection complicated by hemolytic uremic syndrome caused by verotoxin-producing Escherichia coli. Clinical Infectious Diseases 31(3): 815-816, 2000

Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia. Saudi Medical Journal 34(2): 171-176, 2015

Characterization of plasmid mediated AmpC producing Escherichia coli clinical isolates from a tertiary care hospital in South India. Indian Journal of Pathology and Microbiology 57(2): 255-258, 2015

Identification of extended spectrum beta lactamases, AmpC and carbapenemase production among isolates of Escherichia coli in North Indian tertiary care centre. Avicenna Journal of Medicine 8(2): 46-50, 2018